AIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer

by Barry101 | Oct 4, 2021 | Press Release, Uncategorized

Finalizes and reports Phase 2 study protocol Expects to submit IND and apply for Fast Track Status with the FDA by October 18, 2021 Selects the Buffett Cancer Center and Erasmus MC as primary study sites OCALA, Fla., Oct. 04, 2021 — AIM ImmunoTech Inc. (NYSE...

AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses

by Barry101 | Sep 30, 2021 | Press Release, Uncategorized

The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in Q4; AIM anticipates that the trial will commence shortly thereafterOCALA, Fla., Sept. 30, 2021 — AIM ImmunoTech Inc. (NYSE American:AIM) today...

AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19

by Barry101 | Sep 28, 2021 | Press Release, Uncategorized

AIM Has Reached Multiple Major Milestones Demonstrating Strong Progress in Developing its COVID-19 PortfolioOCALA, Fla., Sept. 28, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application...

AIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therapy that May Also Confer Enhanced Immunity to a Wide Range of Respiratory Viruses

by Barry101 | Sep 27, 2021 | Press Release, Uncategorized

OCALA, Fla., Sept. 27, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced the filing of a provisional patent application for Ampligen as a potential early-onset intranasal therapy designed to enhance and expand infection-induced immunity, epitope...

AIM ImmunoTech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-COVID-19 Cognitive Dysfunction

by Barry101 | Sep 21, 2021 | Press Release, Uncategorized

OCALA, Fla., Sept. 21, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced positive progress with the company’s meeting request to the U.S. Food and Drug Administration (FDA) concerning a Phase 2 clinical study of Ampligen as an infusion...

AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial Using its Drug Ampligen

by Barry101 | Sep 20, 2021 | Press Release, Uncategorized

OCALA, Fla., Sept. 20, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today provided a status update on its Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal prophylactic therapy using a human rhinovirus...